Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Adial Pharmaceuticals (NASDAQ: ADIL) has partnered with iRemedy Healthcare to distribute the FaStep COVID-19 IgG/IgM rapid antibody test kits to healthcare providers across the U.S. The tests, which receive FDA emergency use authorization, yield results in just 10 minutes with high accuracy rates of 97.3% for IgG and 99.1% for IgM. This collaboration seeks to address the pressing market need for efficient testing solutions amid the COVID-19 crisis. CEO William Stilley highlighted the role of these tests in enhancing safety during their ongoing clinical trial for AD04, a treatment for Alcohol Use Disorder.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 14-16, 2020. CEO William Stilley will present on September 16 at 1:30 p.m. ET, with a live webcast available. Adial focuses on addiction treatments, with its lead drug AD04 targeting Alcohol Use Disorder (AUD) via a genetic approach. A Phase 2b trial showed significant effectiveness in reducing drinking behaviors without serious safety concerns. AD04 may also help treat other addictions such as opioids and gambling.
Adial Pharmaceuticals (NASDAQ:ADIL, ADILW) announced its participation in the LD Micro 500 Virtual Investor Conference from September 1-4, 2020. The CEO, William Stilley, will present on September 2 at 3:20 p.m. ET, with a live webcast available. The conference showcases key players in the small and micro-cap sector, featuring one-on-one meetings via video calls. Adial is focused on developing treatments for addictions, particularly its lead product AD04, currently in Phase 3 trials for Alcohol Use Disorder. For more information, visit Adial's website.